PCC at ASCO 2025
Scientific Steering Committee
A Scientific Steering Committee, featuring leading oncologist and pathologist key opinion leaders, was held on Friday, May 30, 2025 to discuss and capture unique insights and recommendations for the Implementation of comprehensive genomic profiling (CGP) into routine clinical practice and the Access and adoption of liquid biopsy (LBx) projects.
In attendance from Precision Cancer Consortium (PCC) were: Collin Churchill, Andrea Stevens, Jay White, Tyler Marquart and Ramin Dowlati.
Steering Committee Attendees
Hear from our Board of Directors and experts on the ground at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting:
ASCO Drop-in 2025
The PCC organized an in-person networking event that brought together companies united by a common mission, including Massive Bio, DeciBio, SOPHiA GENETICS, The Synergist, and others.
The event served as a platform for industry members to highlight their impressive work and engage with PCC members and partner advocates about PCC-supported initiatives.
Wayfinder Awards Ceremony 2025
Gabriele Allegri, PCC Chair and Vice President for Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine
John Longshore, PCC Vice Chair and Head of Scientific Affairs for Global Oncology Diagnostics, AstraZeneca
Nicole St Jean, Former PCC Chair and Current Head of Precision Medicine, External Innovation & Partnerships, GSK
Our dedicated members and partner advocates were celebrated during our Wayfinder awards ceremony to recognize their expertise, commitment, and collaboration that have been critical to the success of the PCC over the last year.
Following an opening statement from the new PCC Chair Gabriele Allegri, Nicole St Jean reflected on the rewarding experience of working alongside Gabriele in her video address. She emphasized how their differing perspectives fostered a rich diversity of thought and leadership within the Consortium.
Nicole expressed strong confidence in Gabriele’s leadership, noting that he is perfectly positioned to guide the PCC forward. She also highlighted the vital support he will receive from John Longshore, stating they will form a “fantastic team to bring the PCC to the next level within the global atmosphere.”
Looking ahead, Nicole affirmed that the PCC remains committed to driving a positive impact in diagnostics and ensuring patient access to testing.
John Longshore has officially taken on the role of PCC Vice Chair for the 2025 term. In his virtual video address, John highlighted one of the PCC’s core missions: advancing CGP to ensure patients have access to targeted therapies.
“Diagnostics should not be a gatekeeper for patients to get access to the most relevant, exciting, and ground-breaking therapies.”
John shared that a major focus for the PCC in 2025 will be driving progress in LBx—a critical evolution beyond traditional tissue biopsy. With increasing numbers of biomarkers and many patients unable to provide sufficient tissue, liquid-based solutions are essential to expand access to precision testing.
He also took a moment to thank Nicole St Jean for her leadership and contributions during her tenure as Chair and expressed his enthusiasm for working closely with Gabriele in the year ahead.
As he steps into this new leadership role, John concluded with a call to action: “I hope you will all join me on this journey as we solve biomarker testing challenges together.”
Gabriele then proceeded to proudly present this year’s Wayfinder Awards to a group of PCC members and partner advocates in recognition of their outstanding contributions and advancing our mission of making precision oncology and CGP the new normal.
For the full list of the 2025 PCC Wayfinders and details of their respective projects, click here.
PCC-200 | July 2025